Elan And Biogen Idec Announce That FDA Will Extend Regulatory Review Period For TYSABRI® For Crohn’s Disease

Posted by Patrick McDowell in Health News | Comments Off

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) yesterday announced that the U.S. Food and Drug Administration (FDA) informed the companies that the Agency will extend its regulatory review of TYSABRI® (natalizumab) as a treatment for Crohn’s disease by up to 3 months. [click link for full article]